Articles tagged with Antibodies
A recent study in Human Vaccines & Immunotherapeutics found that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix are non-inferior to three doses, providing similar protection against cervical cancer. The two-dose schedule showed a clinically acceptable safety profile and induced strong antibody responses.
IRC Researchers discover a new function of AID, an enzyme crucial for the immune response. This finding helps explain hyper-IgM syndrome type 2 (HIGM2), a rare genetic disorder that causes an immunodeficiency syndrome.
Researchers use shrink wrap to boost signal of fluorescent markers in biosensing, enabling detection of infectious diseases with lower limits of detection. The technique could lead to a low-cost, highly sensitive diagnostic device using common, everyday materials.
The NIH has awarded a five-year grant of up to $28 million to establish a center for excellence in finding an antibody cocktail to fight the deadly Ebola virus. Researchers from 15 institutions, led by Erica Ollmann Saphire at Scripps Research Institute, will collaborate on definitive experiments.
Researchers have identified a subclass of antibodies associated with an effective immune response to an HIV vaccine. The study provides key insights that could aid the development of new vaccines, focusing on understanding the underlying quality of the immune response.
Two studies found that only one subclass of V1V2-directed IgG antibodies, the IgG3 subclass, is associated with antiviral responses linked to the reduced risk of HIV infection seen in the RV144 trial. More research is needed to determine whether these antibodies protected some vaccinees from HIV infection.
University of Houston researchers create a system to diagnose diseases in real time using smartphones and $20 lens attachments. The device uses gold nanoholes to detect chemical interactions between disease-causing agents and antibodies, providing quick and affordable readouts.
Researchers developed biomolecular tweezers to precisely stretch cells and molecules, studying biochemical activity and receptor binding. The device enables high-throughput capability for assessing the effects of mechanical forces on a broad scale.
Researchers at Cornell University have developed a new type of antibody, called a ubiquibody, which can target specific proteins for destruction. This technology could provide a powerful way to fine-tune research on protein deletion or reduction, and may also prove useful for future drug therapies.
A study found that MERS-CoV is prevalent in camels throughout Saudi Arabia, with antibodies detected in 74% of camels and active virus in 35% of young camels. The virus likely spreads through respiratory secretions.
A new treatment approach in radioimmunotherapy has shown a high overall response rate of 94.4% and complete response in 69.4% of patients with follicular lymphoma. Researchers have found the treatment to be feasible and safe with minimal side effects.
A study has found that invading grey squirrels may pass a deadly virus to native red squirrels through their urine, parasites and faeces. The research also suggests the disease persists best in warm dry conditions and could be slowed by limiting contact between species.
Researchers studying cow antibodies have gained insights into the diversity of human antibodies, which is crucial for recognizing and neutralizing pathogens. The unique structure of these cow antibodies may also be useful for antibody-based therapies or diagnostics.
A Caltech-developed method for delivering HIV-fighting antibodies has been shown to be effective in preventing vaginal transmission of the virus in mice, a breakthrough that could potentially lead to new prevention strategies for humans.
Researchers at The Scripps Research Institute found a protein, Protein M, that attaches to antibodies and prevents them from binding to their target, helping bacteria evade the immune response. This discovery could lead to new antibacterial therapies and tools for research and drug development.
Researchers developed an antibody blocking coagulation factor XII, which prevents thrombosis without increasing bleeding risk in clinical settings. This innovation reduces the clotting risk in emergency situations like ECMO treatment and cardiovascular surgery.
Researchers at Yale University found that a combination of hydroxychloroquine may partially reverse the detrimental effects of antiphospholipid antibodies on human placental cell function, potentially benefiting pregnant women with lupus and/or antiphospholipid syndrome. This could lead to improved pregnancy outcomes for these patients.
A multinational project led by Dr. Tyler Curiel aims to develop an antibody that can block a specific cancer metabolic pathway and reduce its ability to suppress the immune system.
Researchers have developed a novel DNA-barcoded antibody sensing approach to analyze hundreds of cancer-related protein markers from miniscule patient samples. This technology enables comprehensive analysis of protein expression patterns in single cells, revealing significant differences between tumors and predicting treatment response.
Researchers at Roche have successfully developed a new technology called Brain Shuttle that efficiently transports investigational antibodies into the brain in preclinical models of Alzheimer's disease. The technology increased target engagement by over 50-fold compared to parent antibodies.
Researchers have successfully constructed a human Fab library and identified a single-domain antibody that specifically targets amyloid-beta 42 oligomers. This breakthrough discovery offers new hope for treating Alzheimer's disease by reducing amyloid-beta burden and improving memory performance.
A Stanford University School of Medicine study found that men with high testosterone levels have a weakened immune response to the flu vaccine, whereas women and men with lower testosterone levels have a stronger response. The study also discovered that testosterone interacts with genes in a way that dampens immune response.
Researchers at LA BioMed developed antibodies to prevent human cell invasion and treat mucormycosis using CotH protein blocker. The study provides groundwork for developing therapies and diagnostic tests for high-risk patients.
Researchers found that HIV-1-specific antibodies and low pH enhance transcytosis of the virus across epithelial cells. This process was enhanced by the FcRn receptor and is influenced by whether or not the antibody neutralizes the virus.
Grand Challenges Canada has awarded $100,000 grants to 83 innovative global health projects addressing disease and healthcare challenges in resource-poor countries. These projects include diagnostic diapers for deadly rotavirus, yogurt-based solutions to pesticide exposure, and storytelling approaches to maternal health.
Researchers have identified the role of the STAT3 gene in immune system memory, revealing how it directs chemical messenger molecules to various destinations. This discovery sheds light on a rare immunodeficiency disorder and may lead to improved vaccines and treatments.
Scientists have discovered an antibody to the protein LRP4, which plays a critical role in enabling the brain to communicate with muscles. This finding explains why some patients with myasthenia gravis may not have any obvious signs of the disease despite having low levels of antibodies.
Researchers found that a specific molecular process controls B cell activation and differentiation, leading to impaired antibody production. The study highlights the importance of genes like IL-21 receptor, STAT3, and CD25 in B cell function, with mutations causing debilitating effects in patients.
A recent study published in Cancer Prevention Research found that women vaccinated with one dose of the human papillomavirus (HPV) vaccine had stable antibodies against HPV viruses in their blood for up to four years. The results challenge previous dogma on protein subunit vaccines requiring multiple doses for long-lived responses.
Berkeley Lab researchers design a programmable nanomaterial inspired by natural antibodies, capable of identifying diverse molecules. The new material resembles 'molecular Velcro' and has promising applications in chemical sensing and catalysis.
Researchers at Nationwide Children's Hospital have found a way to overcome the immune system's attack on gene therapy viruses. By using plasmapheresis, a process that temporarily removes antibodies from the body, they were able to increase gene expression in animals with Duchenne muscular dystrophy by 500 percent.
A recent study highlights the issue of poor antibody performance due to contaminating hitchhiker antigens. This can lead to misdiagnosis, incorrect conclusions about disease mechanisms, and costly mistakes in drug development.
Researchers have discovered a novel way to generate antibodies that target multiple flu viruses, offering new hope for developing a single vaccine against all strains. The study used the immune suppressant rapamycin to shift the immune response and favor production of broadly specific antibodies.
A new study reveals that fewer US adolescents have antibodies against herpes simplex virus type 1 (HSV-1), making them more susceptible to genital infections. The prevalence of HSV-1 antibodies declined among 14-19 year olds by nearly 23% and among 20-29 year olds by over 9%.
Researchers identify novel gene mutation in NFKB2 that impairs antibody production and fight infection, leading to common variable immunodeficiency (CVID). The discovery provides a new mechanism for immune deficiency and enables early diagnosis and treatment.
Scientists at USC created a mathematical model to predict the biological process creating antibody diversity. The research, a collaboration between Myron Goodman and Chi Mak, explains how an enzyme initiates hypermutations in immunoglobulin genes, generating robust immune systems.
Chemists at Scripps Research Institute develop new technique to create more stable antibody-drug conjugates, reducing toxicity and increasing efficacy. The new method uses a novel Thiol-Click reaction to form stronger linkages with cysteine amino acids.
A clinical trial found that a booster dose of the new meningitis B vaccine at 40 months of age can overcome waning immunity induced by infant vaccination, showing high antibody levels in 89%–100% of children against most strains.
A study published in PeerJ found that nearly 50% of scientific resources are unidentifiable due to a lack of detail in journal articles. Researchers developed guidelines for reporting research resources to aid reproducibility, but these did not improve identification rates.
Dermatomyositis patients with antibodies against NXP-2 and TIF-1γ have a high risk of cancer, according to new tests developed by researchers. The assays detect these specific proteins in patient blood samples, helping clinicians identify those at highest cancer risk.
Researchers suggest that anti-PD-1 antibodies could be effective in treating hepatitis C and other persistent viral infections. The study found that animal models with HCV infection showed improved immune function after treatment with PD-1 blocking antibodies.
A new recombinant antibody can detect and isolate mesenchymal stem cells (MSCs) from umbilical cord blood, a nonembryonic source with promising applications in tissue engineering and blood stem cell transplantation. The antibody recognizes an i blood group antigen present on MSCs.
Researchers have developed a new diagnostic approach combining antibody and genetic tests to detect coeliac disease in Australians. The study found that more than half of the population has genetic risk factors for developing coeliac disease.
A study found that piglets receive maternal IgA, IgG and IgM antibodies against Cystoisospora suis in the colostrum, which decline after two weeks. High levels of these antibodies are associated with reduced severity of neonatal diarrhoea.
A new strategy developed at UC Davis Health System tests for telltale antibodies in the blood to detect tuberculosis, potentially improving treatment outcomes. The test can detect about 80% of active TB cases, making it a significant advancement in disease detection.
Researchers found antibodies specific to MERS-CoV in 100% of serum samples from dromedary camels in Oman, but not in animals from other countries. This suggests that a MERS-CoV-like virus is circulating in dromedary camels, potentially serving as an animal reservoir for the human coronavirus.
Researchers tracked the movement of specialized cells to shed light on the immune system's response to invading pathogens. The study found that T follicular helper cells continually move between germinal centers within lymph nodes, potentially enhancing antibody production.
Researchers discover that prion protein has a 'switch' controlling its toxicity, which can be triggered by antibodies targeting the flexible tail. The study finds that only antibodies targeting the tail are suitable for use as potential drugs, while those triggering the switch are harmful.
University of Alberta researchers have made a breakthrough in understanding prion protein interactions, paving the way for designing molecules that can block prion infection. The discovery opens up possibilities for treating human victims and preventing livestock diseases such as BSE.
Researchers at the IRCM isolated two important mechanisms that improve antibody quality, providing a new model for studying auto-immune diseases. The study found that these mechanisms, class switching and affinity maturation, are crucial for immune responses to infections and diseases.
A study published in PLOS ONE found that children with autism have higher levels of gluten antibodies than those without autism. The researchers also discovered an association between the elevated antibodies and gastrointestinal symptoms in affected children. However, no connection was found to celiac disease.
Researchers have found antibodies against the human papillomavirus (HPV) that may help predict individuals at risk of HPV-related oropharyngeal cancer. The study found that these antibodies were detectable in nearly 35% of patients with cancer, compared to less than 1% of those without cancer.
A new study on an anti-nicotine vaccination found mixed results, with some patients experiencing a decrease in brain nicotine accumulation but others showing an increase. The study used PET imaging to test the vaccine's effectiveness, revealing that high-affinity antibodies were associated with decreased brain nicotine accumulation.
Scientists at Scripps Research Institute have identified an extraordinary family of cow antibodies that could lead to breakthroughs in human medicine. The unique structure and mechanism of these antibodies may allow for the creation of new therapeutic proteins.
Traumatic brain injuries generate toxic tau oligomers that cause nerve cells to clump together and spread to other parts of the brain. These damaging protein assemblages can contribute to memory deficits, seizures, and disruptions in the sleep-wake cycle.
Scientists at Emory Vaccine Center found that IL-21 is necessary for long-lasting antibody responses in mice against viral infections. The molecule stimulates germinal centers and supports T helper cells, leading to the generation of virus-specific long-lived plasma cells.
A new study reveals that the level of immunity to the recently circulating H7N9 influenza virus in an urban and rural population in Vietnam is very low. The findings suggest that people living in this area have had little or no exposure to the virus, making it essential to consider alternative plans for pandemic preparedness.
Researchers at Lund University are testing an antibody-based treatment for multiple myeloma, a type of blood cancer without a cure. The antibody, BI-505, has shown promising results in cell studies and animal experiments, and a clinical trial is currently underway to test its effects on patients.
Researchers analyzed data from the RV144 HIV vaccine trial, which showed a 31% protection rate. They found that specific antibodies may interfere with the protective effects of other antibodies, reducing the vaccine's efficacy. This discovery can inform future vaccine development strategies to overcome these limitations.
Research found pregnant women with mid to high levels of anti-tTG antibodies are at risk for having reduced fetal weight and birth weight. Fetuses of women with positive anti-tTG weighed 16 grams less during the second trimester, while those with intermediate anti-tTG levels were 53 grams lighter.